Compare Nordic American Tankers Limited Common Stock (NAT) vs Novo Nordisk A/S (NVO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Nordic American Tankers Limited Common Stock vs Novo Nordisk A/S — how do they compare? Nordic American Tankers Limited Common Stock trades at $7.94 (market cap $1.74B), while Novo Nordisk A/S trades at $39.58 (market cap $169.24B). The key difference: Novo Nordisk A/S is far larger — about 97.3× Nordic American Tankers Limited Common Stock's market cap, and Nordic American Tankers Limited Common Stock pays the higher dividend (13.15%). Which is the better fit depends on your goals — on Pluang, investors hold Nordic American Tankers Limited Common Stock for 0 Days and Novo Nordisk A/S for 116 Days on average.
| NAT | NVO | |
|---|---|---|
Market Cap | $1.74B | $169.24B |
Volume | 8,906,830 | 9,314,273 |
Sector | Industrials | Health |
52-Week High | $8.79 | $63.98 |
52-Week Low | $3.26 | $35.29 |
Typical Hold Time | 0 Days | 116 Days |
Enterprise Value | $2.01B | $187.94B |
Dividend Yield | 13.15% | 4.71% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
NAT trades at $8.79, matching its 52-week high, reflecting strong momentum amid favorable tanker market conditions. The stock shows robust fundamentals with a 33.34% net income margin and 25.66% ROE for 2026, while Q2 2026 EPS beat expectations. Technical indicators are neutral, with support and resistance clustered around $9. Recent news highlights surging spot rates and insider buying by the Hansson family, underscoring confidence in near-term prospects.
Outlook is positive due to elevated freight rates and earnings growth, but risks include volatility in tanker rates and geopolitical tensions. Analysts are mixed with a $3.50 consensus target, suggesting caution despite operational strength. The stock's high yield and momentum offer appeal, though sustainability of current rates remains a key monitorable.
Novo Nordisk (NVO) trades at $38.06, down 1.35% with bearish technical signals despite strong fundamentals. The stock shows robust profitability with 35.35% net margins and consistent earnings beats. Recent FDA delays for hemophilia drug denecimig and competitive pressure from Eli Lilly's obesity drug pipeline create near-term headwinds. Technical indicators show RSI at overbought levels with resistance at $39.
Despite current technical weakness, NVO maintains strong fundamentals with 59% ROE and attractive valuation at 9.32 P/E. Analyst consensus remains bullish with $42.33 price target (11% upside). Key risks include regulatory delays and intensifying GLP-1 competition. The company's $4B licensing deals and oral Wegovy development provide long-term growth catalysts.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Nordic American Tankers Limited Common Stock
Nordic American Tankers Limited is a Bermuda-based shipping company specializing exclusively in Suezmax crude-oil tankers, which it charters in the spot and period markets on international routes. The company has paid a dividend every quarter since 1997.
Read more on NAT →About Novo Nordisk A/S
With almost 50% market share by volume of the global insulin market, Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments, and oral antidiabetic agents. Novo also has a biopharmaceutical segment (constituting roughly 15% of revenue) that specializes in protein therapies for hemophilia and other disorders.
Read more on NVO →
